Atelerix Life Sciences

Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis

Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief

Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBCs) to prevent or reverse life-threatening opioid-related side effects.

CLICK TO READ ARTICLE